Isolated spinal Rosai–Dorfman disease with secondary hypertrophic pachymeningitis: A case report with 20-year follow-up, highlighting rapid recurrence and de novo lesion formation Authors: Prasert Iampreechakul, Chonlada Angsusing, Yodkhwan Wattanasen, Sunisa Hangsapruek, Punjama Lertbutsayanukul, Samasuk Thammachantha, Metha Apiwattanakul, Somkiet Siriwimonmas Published: 2026 ABSTRACT Background: Rosai-Dorfman disease (RDD) is a rare, benign histiocytic disorder that typically presents with cervical lymphadenopathy but may involve extranodal sites in up to 40% of cases. Isolated spinal RDD without systemic manifestations is exceedingly rare and often mimics more common neoplastic or inflammatory spinal pathologies. When associated with hypertrophic pachymeningitis (HP), the condition may demonstrate an aggressive and relapsing course, posing significant diagnostic and therapeutic challenges.Case Description: We report the case of a 41-year-old male who presented in 2005 with progressive paraparesis and voiding difficulty. Magnetic resonance imaging revealed an intradural extramedullary lesion compressing the cervical spinal cord from C5 to T1. Surgical resection was performed with a presumptive diagnosis of meningioma. Histopathology confirmed RDD with secondary HP. One month after surgery, the patient experienced early recurrence, which was managed with corticosteroids and azathioprine. Six years later, a de novo lesion developed at the thoracic level and responded to a short course of corticosteroid therapy. No further immunosuppressive treatment was required after 2015, and the lesion has remained stable without neurological symptoms. Serial imaging over 20 years demonstrated both regression and stability of the disease, illustrating its chronic, relapsing nature.Conclusion: This case represents one of the longest documented follow-ups of isolated spinal RDD with secondary HP. It highlights the potential for both early recurrence and delayed de novo lesion formation, even after apparent disease control. Surgical decompression remains essential for diagnosis and initial treatment, but long-term management may require tailored immunosuppressive strategies and sustained clinical and radiologic surveillance. INTRODUCTION Rosai–Dorfman disease (RDD), also referred to as sinus histiocytosis with massive lymphadenopathy, is a rare, benign histiocytic proliferative disorder of uncertain etiology.[10] While it typically presents with painless cervical lymphadenopathy, extranodal involvement is observed in approximately 40% of cases and may affect diverse sites including the skin, orbit, respiratory tract, bone, and central nervous system (CNS).[1] CNS involvement is uncommon, reported in fewer than 5% of RDD cases, and isolated spinal manifestations without systemic or nodal disease are exceedingly rare.[21,26] Spinal RDD presents significant diagnostic challenges due to its clinical and radiological resemblance to more common spinal tumors such as meningiomas or schwannomas. Patients may exhibit progressive neurological deficits secondary to spinal cord or nerve root compression.[2] Magnetic resonance imaging (MRI) frequently reveals dural-based, homogeneously enhancing lesions, often leading to misdiagnosis.[3] Histopathological confirmation is essential, characterized by the presence of emperipolesis, S100 and CD68 positivity, and absence of CD1a, which helps differentiate RDD from other histiocytic disorders.[20] Hypertrophic pachymeningitis (HP) is a chronic inflammatory condition involving fibrous thickening of the dura mater. It may occur idiopathically or as a secondary phenomenon associated with autoimmune, infectious, or neoplastic conditions.[17,23] When HP develops in association with RDD, it may reflect a more diffuse immune-mediated process that complicates the disease course and therapeutic approach.[22] This study presents a rare case of isolated spinal extranodal RDD complicated by secondary HP, with a clinical course followed over 20 years. The case is distinguished by early postoperative recurrence, delayed development of a de novo lesion at a separate spinal level, and eventual spontaneous remission. This report underscores the relapsing and chronic nature of spinal RDD, the importance of individualized treatment strategies, and the critical need for long-term clinical and radiological surveillance. CASE DESCRIPTION In April 2005, a 41-year-old male presented with a 1-month history of low back pain radiating to both legs, followed by progressive paraparesis and voiding difficulty. Neurological examination revealed spastic paraparesis with motor strength graded 2/5 in the lower extremities, absence of pinprick sensation below the T10 level, and bilateral positive Babinski sign and clonus. MRI of the entire spine demonstrated an intradural extramedullary lesion with a broad dural base located along the anterior spinal canal from C5 to T1. The lesion was isointense on T1-weighted images, hypointense on T2-weighted images, and showed homogeneous enhancement after contrast administration. Significant anterior cervical cord compression with T2 signal hyperintensity at the C6–C7 levels was noted, suggestive of possible ischemic myelopathy [Figure 1]. A provisional diagnosis of spinal meningioma was made. Preoperative magnetic resonance imaging of the cervical spine obtained in April 2005. (a-c) Sagittal T1-weighted, T2-weighted, and contrast-enhanced T1-weighted images, and (d and e) axial contrastenhanced T1-weighted images at the C6–C7 and C7 levels demonstrate an intradural extramedullary lesion with a broad dural base along the anterior spinal canal from C5 to T1. The lesion is isointense on T1-weighted images, hypointense on T2-weighted images, and shows homogeneous enhancement postcontrast. Significant anterior cervical cord compression is noted at the corresponding levels. The patient underwent C6–C7 corpectomy with near-total excision of the lesion, followed by anterior cervical plate fixation and iliac bone graft fusion. Intraoperative findings revealed a markedly thickened dura and a firm, whitish-gray mass causing significant compression of the spinal cord. The lesion was mildly vascularized and exhibited no evidence of intramedullary invasion. Near-total resection was accomplished using an ultrasonic aspirator, and adequate spinal cord decompression was achieved [Figure 2]. The postoperative course was uneventful. Intraoperative photographs of the anterior cervical approach under the operating microscope following C6–C7 corpectomy in the supine position. (a) Opening of the thickened dura. (b and c) Removal of the intradural mass by trimming and thinning the lesion using an ultrasonic aspirator. (d) The exposed residual mass. (e) Attempt to elevate the residual mass en bloc using forceps and divide it with scissors. (f) The anterior surface of the spinal cord after near-total removal of the lesion. Histopathological analysis of the resected tissue showed dense lymphocytic infiltration and occasional macrophage aggregation within fibrous connective tissue and dural fragments. Microscopic examination revealed dilated vascular channels containing mixed inflammatory cells. Large foamy histiocytes engulfing intact mature lymphocytes and plasma cells were observed, demonstrating emperipolesis, which is a characteristic feature of RDD. Special stains for microorganisms, including Gram stain, acid-fast bacilli (AFB), periodic acid–Schiff, and Grocott methenamine silver, were all negative. These findings are consistent with chronic secondary pachymeningitis due to RDD [Figure 3]. The patient’s lower extremity motor function gradually improved following surgery. (a) Microscopic section showing dilated vascular structures containing mixed inflammatory cells (Hematoxylin and Eosin [H&E], ×200). (b) Large foamy histiocytes engulfing intact mature lymphocytes and plasma cells, demonstrating emperipolesis (circle), a characteristic feature of Rosai-Dorfman disease (H&E, ×400). A follow-up MRI in May 2005, 1 month after surgery, revealed a residual or recurrent enhancing intradural extramedullary lesion along the anterior cervical canal from C6 to T1, which remained hypointense on T2-weighted imaging. The cervical spinal cord showed reduced compression; however, persistent T2 hyperintensity at the C7 level was noted, consistent with chronic compressive myelopathy [Figure 4]. Intravenous dexamethasone was initiated, followed by oral prednisolone. After 1 month, the patient developed Cushingoid features, prompting a gradual taper of corticosteroids. Azathioprine (50 mg twice daily) was subsequently introduced as a steroid-sparing agent, while the patient continued on a reduced dose of prednisolone. Before discharge, motor strength in the lower limbs had improved to Grade IV, and the patient was ambulatory with a walker. He declined further surgical intervention. Serial MRI performed every 3 months demonstrated gradual regression of the residual lesion. Oral prednisolone was fully discontinued by December 2005. Magnetic resonance imaging of the cervical spine one month postoperatively (May 2005). (a, b) Sagittal T2-weighted and contrast-enhanced T1-weighted images, and (c, d and e) sequential axial contrast-enhanced T1-weighted images at the C7 level demonstrate postoperative anterior cervical spine fixation with an enhancing intradural extramedullary lesion along the anterior spinal canal from C6 to T1. The lesion remains hypointense on T2-weighted imaging. There is reduced mass effect on the cervical cord, with persistent T2 hyperintensity at the C7 level, compatible with chronic compressive myelopathy. In February 2006, MRI showed complete disappearance of the cervical lesion [Figure 5a], and azathioprine was tapered off over the following 4 months. MRI in January 2009 confirmed no recurrence [Figure 5b]. The patient achieved full neurological recovery, with only mild persistent numbness in both feet [Figure 6]. Follow-up magnetic resonance imaging of the cervical spine. (a) Sagittal T1-weighted, contrastenhanced T1-weighted, and T2-weighted images obtained in February 2006 demonstrate no residual or recurrent intradural extramedullary lesion. (b) Sagittal T1-weighted, contrast-enhanced T1-weighted, and T2-weighted images obtained in January 2009 also show no evidence of residual or recurrent disease. Persistent focal T2 hyperintensity is seen at the C7 level, compatible with chronic compressive myelopathy. Photograph obtained in 2009 showing the patient standing on the right leg with both arms extended, demonstrating good motor function and balance. In June 2011, the patient developed bilateral leg pain and tightness. Cervical MRI revealed a newly developed small enhancing intradural extramedullary lesion at the right posterior spinal canal at the T2 level. The lesion was hypointense on T2-weighted images and exhibited a dural tail sign [Figure 7]. MRI of the brain was unremarkable. He was treated with intravenous methylprednisolone (1 g every 6 h for 5 days), followed by oral prednisolone, which resulted in marked clinical improvement. Follow-up MRI 1 month later showed a reduction in lesion size. Prednisolone was gradually tapered and discontinued by December 2012. Subsequent MRIs were performed annually. Follow-up magnetic resonance imaging of the cervical spine obtained in June 2011. (a and b) Sagittal T2-weighted and contrast-enhanced T1-weighted images, and (c and d) sequential axial contrastenhanced T1-weighted images at the T2 level demonstrate a newly developed small enhancing intradural extramedullary lesion at the right posterior aspect of the spinal canal at T2. The lesion is hypointense on T2-weighted imaging and exhibits a dural tail sign on the sagittal view. In November 2015, the patient experienced an allergic reaction to intravenous contrast during MRI. He was treated with intravenous hydrocortisone for 2 days and a short course of oral prednisolone for 1 week. Without further use of corticosteroids, follow-up MRIs between 2015 and 2025 demonstrated progressive regression of the T2-hypointense enhancing lesion at the T2 level. By the end of the observation period, only a thin residual area with faint contrast enhancement remained [Figure 8]. Sequential follow-up magnetic resonance imaging (MRI) of the cervical spine. (a–d) Sagittal and axial T2-weighted images and sagittal and axial contrast-enhanced T1-weighted images obtained in November 2015, March 2018, November 2022, and October 2025 demonstrate progressive regression of the enhancing T2-hypointense intradural extramedullary lesion (arrowheads) at the right posterior aspect of the spinal canal at T2. A thin, small residual T2-hypointense lesion with faint enhancement remains. At present, the patient remains neurologically intact and in good general health. He undergoes routine clinical follow-up every 6 months, with plans for MRI surveillance every 2–3 years. DISCUSSION Isolated RDD of the spine RDD is a rare benign histiocytic proliferative disorder. While it typically presents with nodal involvement, particularly in the cervical region, extranodal manifestations occur in more than 40% of cases. CNS involvement remains uncommon, seen in fewer than 5% of patients.[14,24,26] Isolated spinal disease accounts for approximately 14% of CNS-RDD cases, while 9% show combined intracranial and spinal involvement.[21] Spinal involvement is more frequently associated with systemic RDD, whereas isolated spinal cases are exceptionally rare.[18] Isolated spinal RDD more commonly affects males and tends to present in the fifth decade of life, with a mean age around 42 years.[2] The thoracic spine is most frequently involved, followed by the cervical region. Lumbar and sacral involvement is less common, and multilevel disease is rare. Anatomically, spinal RDD is diverse. Lesions have been reported in extradural, intradural, extramedullary, intramedullary, and osseous (vertebral) locations.[20] This variability reflects the disease’s ability to affect both extra-axial and intra-axial compartments of the spine, contributing to a wide range of clinical symptoms and presenting unique diagnostic and surgical challenges. Diagnosis is often difficult, as the disease lacks specific clinical or radiological features. MRI usually shows lesions that are isointense to hypointense on T1- and T2-weighted sequences with homogeneous contrast enhancement. These characteristics can resemble meningiomas or schwannomas, particularly when a dural tail is present, leading to frequent preoperative misdiagnosis.[3,9,20] Histopathological evaluation with immunohistochemistry is essential for a definitive diagnosis. Microscopically, RDD demonstrates emperipolesis and positive staining for S100 and CD68, while CD1a is typically negative, helping to exclude Langerhans cell histiocytosis. Although emperipolesis is a hallmark feature, it may be subtle or absent in up to 30% of CNS cases, further highlighting the importance of immunohistochemical analysis in establishing the correct diagnosis.[4,20,26] Management approaches and treatment response in spinal RDD The management of spinal RDD is largely individualized due to its rarity and variable clinical presentation. Surgical resection remains the primary treatment in patients with neurological deficits, offering both diagnostic and therapeutic benefits by facilitating tissue diagnosis and relieving spinal cord compression. While complete (gross total) resection is preferred, it is often constrained by dense dural adhesions and the risk of spinal cord injury.[2,20] In such situations, subtotal resection may be sufficient to achieve symptomatic relief. For asymptomatic individuals or those without neurological compromise, a conservative observation strategy may be appropriate.[9] Adjuvant therapies are frequently employed in cases of residual, recurrent, unresectable, multifocal, or anatomically challenging lesions, although no standardized treatment protocols currently exist. Corticosteroids are the most commonly used agents, often producing clinical improvement. Additional modalities include chemotherapy, radiotherapy, and immunomodulatory drugs such as thalidomide, which have been used with varying success.[1,3,11,12,16,18,19,26] Systemic treatments like rituximab and imatinib have shown promise in disseminated forms of RDD but lack robust evidence in cases involving the CNS.[18] Selection of adjuvant therapy is guided by disease extent, anatomical location, patient comorbidities, and prior treatment response. When a multimodal approach is used, outcomes are generally favorable.[21,24] Notably, patients with intradural-extramedullary lesions and those undergoing gross total resection tend to achieve better neurological recovery, whereas intramedullary involvement is associated with poorer prognostic outcomes.[2] Recurrence and de novo lesion development in spinal RDD Although spinal RDD is histologically benign, it may demonstrate aggressive local behavior and an unpredictable clinical course characterized by episodic relapses and remissions.[19] Reported recurrence rates vary, reaching up to 20% in cases involving incomplete resection or diffuse dural infiltration.[2,9,21] The average time to recurrence is approximately 19.5 months, though some cases recur as early as 1 month after treatment. This variability suggests that residual microscopic disease or underlying multifocal pathology may contribute to early relapse, highlighting the need for close postoperative surveillance. Notably, recurrence does not consistently correlate with the extent of resection, underscoring the biologic unpredictability of RDD.[3] Despite this, gross total resection remains the preferred surgical approach when feasible. Lesions located in intradural extramedullary or intramedullary compartments carry a higher risk of recurrence, and deeper spinal involvement requires particularly vigilant long-term monitoring.[2,11] The potential for delayed disease progression further reinforces the classification of RDD as a chronic inflammatory disorder. Intracranial RDD has shown the capacity to develop anatomically distinct lesions years after apparent remission, and similar delayed manifestations have been observed in the spine.[12,15,19] RDD can also arise de novo in extraspinal sites such as the tibia.[1] These patterns likely reflect persistent immune dysregulation and cytokine-mediated histiocytic activation rather than localized recurrence. The ability of RDD to form new lesions long after initial treatment emphasizes the need for sustained clinical and imaging follow-up. Clinicians should maintain a high index of suspicion for new spinal involvement in patients with a known history of RDD, even in the absence of prior spinal lesions. A review of published cases with at least 5 years of follow-up [Table 1][3,13,26] illustrates the broad anatomical spectrum and variable outcomes. While most patients benefited from surgical and adjuvant therapy, recurrence still occurred in some despite complete resection. Our case, with a 20-year follow-up, is unique for documenting both early recurrence and delayed de novo lesion development, affirming the relapsing course of spinal RDD. Table 1:Summary of reported cases of spinal Rosai–Dorfman disease with long-term follow-up of at least 5 years. Summary of reported cases of spinal Rosai–Dorfman disease with long-term follow-up of at least 5 years. Spinal HP HP is an uncommon chronic inflammatory disorder characterized by focal or diffuse thickening and fibrosis of the dura mater. Spinal involvement is significantly less common than cranial, and isolated spinal HP presents considerable diagnostic and therapeutic challenges. The etiologies of spinal HP can be broadly classified as idiopathic or secondary. Secondary forms are associated with systemic autoimmune conditions such as antineutrophil cytoplasmic antibody -associated vasculitis, rheumatoid arthritis, and immunoglobulin G4 (IgG4)-related disease, as well as infections and neoplastic processes.[23] Management strategies for spinal HP are guided by the underlying cause and the severity of neurological symptoms. Idiopathic cases typically respond to corticosteroid monotherapy, while secondary HP often requires targeted treatment of the associated systemic condition. Surgical decompression is indicated in patients with significant spinal cord compression or progressive neurologic deficits. Although outcomes vary, many patients experience neurological improvement with appropriate medical or surgical intervention, as documented in long-term follow-up studies of both idiopathic and secondary HP.[17] Despite treatment, spinal HP often follows a relapsing course. Recurrence is most frequently observed within the 1st year after initial therapy. In such cases, steroid-sparing immunosuppressive agents such as azathioprine, methotrexate, cyclophosphamide, or rituximab are commonly employed.[4] Choi et al.[8] reported an aggressive case of thoracic spinal HP that recurred rapidly following surgical decompression. The lesion exhibited marked dural fibrosis and ongoing inflammatory activity despite repeat surgery, with limited neurological recovery. This case illustrates the potential for HP to behave as a refractory inflammatory condition, particularly when resection is incomplete or dural involvement is extensive. It emphasizes the need for close clinical monitoring and consideration of adjunctive immunosuppressive therapy when appropriate. RDD, though rare, has been identified as a secondary cause of HP and demonstrates notable morphological variability.[22] Some of the cases present as well-demarcated intradural masses that mimic benign tumors such as meningiomas on imaging and during surgery.[5] In contrast, our case involved diffuse dural thickening with dense fibrotic tissue forming an ill-defined infiltrative mass that was difficult to resect. This variation highlights the morphological spectrum of spinal RDD, which may present either as a localized, tumor-like lesion or as a widespread fibro-inflammatory process with limited surgical accessibility. These differences are likely influenced by disease chronicity, stage, and immune-mediated mechanisms. In our case, the clinical course, intraoperative findings, and pathological features were consistent with secondary HP associated with RDD. Based on comparisons with other cases of primary and secondary spinal HP, this classification accounts for the observed dural fibrosis and inflammatory changes, supporting the concept of RDD as part of a broader inflammatory spectrum involving the spinal dura. The role of systemic immune dysregulation in RDD-associated HP The pathogenesis of RDD, once considered idiopathic, is now increasingly associated with immune dysregulation. As early as 1976, Kessler et al. proposed that RDD might result from an aberrant immune response or an infection-induced immunologic process, based on observations of impaired cellular immunity and the presence of emperipolesis, a histological feature common to other immune-mediated conditions.[10] The observed decline in emperipolesis during later stages of the disease was interpreted as a reflection of evolving disease biology, lending further support to the concept of a dynamic, immune-driven process.[10] Subsequent clinical observations have reinforced this hypothesis. Tezuka et al.[22] described a 72-year-old man with RDD complicated by diffuse HP, manifesting with progressive cranial neuropathies and extensive dural thickening that was not amenable to surgery. The patient responded remarkably to intermittent high-dose intravenous methylprednisolone, which provided rapid and sustained clinical and radiologic improvement over 4 years. The superior efficacy of intravenous methylprednisolone over oral corticosteroids was attributed to its enhanced CNS penetration and stronger anti-inflammatory activity. Polyclonal hypergammaglobulinemia with normal IgG4 levels in this case supported a reactive immune process, aligning with the concept of systemic immune dysregulation as the driving mechanism. A similar theme was observed in the case reported by Xu et al.,[25] involving a 28-year-old woman with multisystem extranodal RDD in conjunction with Sjögren’s syndrome, panuveitis, and HP. Her presentation included CNS and ophthalmologic involvement, positive anti-SSA/SSB antibodies, and polyclonal hypergammaglobulinemia, all of which suggested autoimmune activation. Histological confirmation of RDD, coupled with an excellent response to systemic corticosteroids, reinforced the immune-mediated nature of the disease and emphasized the importance of early recognition and immunosuppressive treatment to prevent irreversible organ damage. The histological overlap between RDD and inflammatory pseudotumor has also been proposed as a framework for understanding RDD-associated pachymeningitis. Govender and Chetty[7] noted that both conditions can present as mass-forming, chronic inflammatory lesions of the dura, with shared features including lymphoplasmacytic infiltrates, fibrosis, spindle cell proliferation, and variable histiocytic prominence. In spinal RDD, this spectrum may reflect a temporal or phenotypic continuum, in which early histiocyte-rich inflammation progresses toward fibro-inflammatory pachymeningeal thickening. This model helps explain the diagnostic and therapeutic challenges posed by RDD and HP, including variable surgical resectability and the tendency for recurrence despite benign histology. Further complexity is illustrated by the case reported by Breiner et al.,[6] in which diffuse CNS RDD occurred alongside multiple sclerosis, a dissecting vertebral artery aneurysm due to RDD-related vasculitis, and polycythemia vera with a Janus kinase (JAK2) mutation. This striking confluence of inflammatory and myeloproliferative disorders raises the possibility of a shared immunopathogenic mechanism, particularly involving dysregulation of the JAK– signal transducers and activators of transcription (STAT) signaling pathway. The presence of chronic inflammatory and vascular complications in this patient underscores the systemic nature of immune activation in RDD and its potential to involve diverse tissue compartments. In summary, mounting evidence supports the concept of RDD as an immune-mediated histiocytic disorder, with HP often representing a secondary manifestation of chronic cytokine-driven inflammation rather than direct histiocytic infiltration alone. The frequent co-occurrence of autoimmune features, polyclonal hypergammaglobulinemia, and steroid responsiveness further reinforces the role of systemic immune dysregulation in disease pathogenesis. Recognition of this underlying mechanism is critical, as it informs both diagnostic evaluation and the selection of effective immunomodulatory therapies, particularly in cases of dural involvement where surgical resection may be limited. Therapeutic dilemma in RDD-associated HP Management of RDD associated with HP presents a clinical dilemma: Whether to prioritize treatment of local mass effects or to focus on systemic immune dysregulation. In cases of isolated or focal RDD, particularly those manifesting as well-circumscribed dural-based lesions, surgical resection remains the primary approach. This strategy allows for both tissue diagnosis and spinal cord decompression and is often associated with favorable neurological outcomes.[2,9,20] Conversely, idiopathic HP is typically managed with immunosuppressive therapy, most commonly corticosteroids, either alone or in combination with steroid-sparing agents such as azathioprine, methotrexate, or rituximab, reflecting its immune-mediated pathogenesis.[17,23] When RDD presents with multifocal, unresectable, or diffuse pachymeningeal involvement, complete resection is often not feasible. In such settings, medical therapy has demonstrated efficacy, with several reports documenting meaningful clinical and radiological responses to corticosteroids and immunomodulatory agents.[1,3,11,12,16,18,19,26]These outcomes suggest that treatment directed at systemic immune dysregulation may be more effective in controlling disease progression than surgical intervention alone. This overlap between RDD and HP supports the hypothesis that RDD-associated HP represents a continuum of immune-mediated dural pathology, requiring an individualized and multidisciplinary treatment strategy that balances surgical and medical approaches.[7] In the present case, intraoperative findings suggested a lesion consistent with HP, and near-total resection was achieved. However, within 1 month, the patient developed rapid local recurrence, which responded to intravenous dexamethasone followed by a combination of oral prednisolone and azathioprine for 15 months. Six years later, a de novo lesion developed and was successfully treated with a short course of intravenous methylprednisolone followed by oral corticosteroids. In 2015, the patient received intravenous hydrocortisone due to an allergic reaction to contrast media, after which corticosteroid therapy was discontinued. Despite cessation of treatment, the lesion has remained stable without neurological deficits, suggesting spontaneous remission. The variability in corticosteroid regimens was due to differing treatment decisions made by multiple neurologists. This case highlights the importance of long-term clinical and radiologic follow-up to monitor disease behavior and guide management. Future studies are essential to refine therapeutic strategies in RDD-associated HP. Key areas of investigation include the timing and selection of immunosuppressive therapies, the role of surgery in disease control, and the identification of biomarkers predictive of recurrence or treatment response. In addition, the potential utility of targeted therapies aimed at cytokine-mediated pathways, such as JAK–STAT signaling, warrants further exploration. Prospective registries and molecularly informed research will be critical in determining whether medical therapy modifies the underlying disease course or merely suppresses inflammatory activity, thereby informing precision-based management in this rare and complex disorder. CONCLUSION Isolated spinal RDD with secondary HP is an extremely rare and diagnostically challenging condition. Although histologically benign, spinal RDD can demonstrate aggressive clinical behavior, including early recurrence and delayed de novo lesion formation. The disease often mimics other dural-based spinal tumors radiologically, making histopathological and immunohistochemical confirmation essential. This case, with a 20-year follow-up, underscores the chronic and relapsing nature of RDD and highlights the importance of long-term clinical and radiological surveillance. The management should be individualized based on symptom severity, anatomical involvement, and response to treatment. Surgical resection remains a key diagnostic and therapeutic tool, while immunosuppressive therapy plays an important role in managing unresectable, recurrent, or multifocal disease. Recognition of the immune-mediated mechanisms underlying RDD-associated pachymeningitis may inform future targeted therapeutic strategies and improve long-term outcomes in affected patients.